Abstract 2048P
Background
Oxycodone is known to have numerous drug-drug interactions (DDIs) that can potentially decrease efficacy or lead to adverse drug reactions (ADRs). However, there is limited research on the frequency of DDIs associated with oxycodone use in patients with cancer. In this study, the frequency and pharmacological and clinical relevance of DDIs between oxycodone and perpetrators were studied in patients with cancer.
Methods
A cross-sectional study was conducted using pharmacy records to study the concomitant use of oxycodone and DDI perpetrators. These perpetrators were registered from oxycodone use trajectories between 1 September 2021 and 1 September 2022 in the Deventer Hospital by consulting Lexicomp®, Micromedex®, the Dutch Kennisbank and the Dutch Commentaren Medicatiebewaking. The clinical relevance of the identified perpetrators was examined by a clinical pharmacologist and a medical oncologist. Additionally, the frequency of multiple interactions was studied.
Results
In 254 oxycodone trajectories, 227 (89.4%) were found to include at least one pharmacologically relevant perpetrator. Of these, 210 (82.7%) were clinically relevant. A total of 80 different pharmacologically relevant perpetrators were identified, with 65 (81.3%) being considered clinically relevant. Interactions were observed in 21 (8.3%) oxycodone trajectories. Dutch compendia generally classified DDIs with oxycodone as less relevant compared to Lexicomp and Micromedex.
Conclusions
A high frequency of pharmacologically and clinically relevant perpetrators of DDIs with oxycodone was observed in our cohort. Moreover, a high number of double interactions involving oxycodone was found. Revision of drug interaction compendia used in Dutch healthcare in accordance with international compendia is recommended to improve pharmacovigilance.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2126P - Exercise implementation into a clinic setting with 1.660 cancer patients: Real-world data from eight years oncological exercise therapy in Cologne (OTT)
Presenter: Timo Niels
Session: Poster session 06
2127P - Long-term yoga reduces the side effects of systemic therapies and improves arm symptoms in the breast cancer patients
Presenter: Mayank Jain
Session: Poster session 06
2128P - exerCise discussion with Oncologist duriNg caNcEr ConsultaTion: The CONNECT study
Presenter: Sara Pilotto
Session: Poster session 06
2129P - Feasibility of a virtual exercise program to mitigate decline in physical function for advanced lung cancer patients
Presenter: Ying Wang, Sarah Yeo
Session: Poster session 06